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Abstract 
It often takes very long before sufficient evidence exists to support implementation of new 
methods into routine screening. Where national screening programmes are already effective, 
switching to a more sensitive screening test may not be a priority. Although risk associated 
with overly rapid implementation exists, a postponement is also associated with – a so far 
unquantified – missed opportunity to prevent deaths. This risk tends not to be addressed 
where effective screening methods are already in use. Here, we estimate the monetary value 
of a one-year delay in replacing cytology cervical screening with human papillomavirus 
(HPV) testing. Using a previously validated model, we calculated the number of incident and 
fatal cervical cancers that would be diagnosed by 2030 in England under the assumption that 
HPV testing replaces cytology in 2020 instead of in 2019, and the monetary value of the 
quality-adjusted life years (QALY) that are lost in these preventable cases. A one-year delay 
in the implementation of HPV screening would miss the opportunity to prevent 581 cases of 
cervical cancer and lead to a loss of 1595 quality-adjusted life years (3.5% discount rate) with 
a monetary value of £32 million (at £20,000 per QALY). This is a measurable loss and 
should be considered in prioritising decision making in screening. 
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Introduction 
In scientific circles there is overwhelming support for replacing cytology with Human 
Papillomavirus (HPV) testing in primary cervical screening, and policy makers in the UK and 
elsewhere are planning for a rollout of HPV-based screening. Yet, it is eye-opening to realise 
that more than 30 years have passed since HPV was first associated with cervical cancer in 
19831 and nearly 20 years since it was established as necessary for the development of 
cervical cancer.2 An algorithm for primary HPV screening with cytology triage was first 
published 15 years ago,3 and results from randomised trials4-6 showing that screening based 
on HPV testing prevents more cervical cancer than cytology screening7 were published 
almost 10 years ago. 
Use of HPV primary testing around the world – current situation 
The United States led the way in introducing HPV-based screening in the mid-2000’s, as an 
adjunct to cytology (also known as co-testing). Countries where call/recall cervical screening 
programmes had yet to be established implemented HPV primary screening soon after, for 
example Mexico (from 2008)8 and Turkey (from 2014)9. By contrast the pace in the EU has 
been considerably slower with HPV screening guidelines only being published in 2015.10 In 
the Netherlands the Health Council announced its support for HPV-based screening in 2011 
and the Ministry of Health made the decision to implement in 2013, but the full 
implementation was delayed from the initial plan in 2016 until early 2017. Denmark 
recommended HPV testing for primary screening in 2012 for women aged 60-65, but the test 
was not rolled out nationally until late 2014; in 2018 they announced that the roll-out to 
women aged 30-59 will begin in 2019. Sweden made the decision to replace cytology with 
HPV testing for women age 30 and above in 2015, with a gradual rollout starting in 2017. In 
Italy, HPV screening was recommended in 2013 and the rollout should be completed by 
2018.11 
HPV primary testing in England 
In England, cervical screening is currently offered through a cytology-based call/recall 
programme 3-yearly to women aged 25-49 and 5-yearly to women aged 50-64. HPV testing 
is reserved for triage of equivocal cytology samples and follow-up after treatment of high-
grade disease. In January 2016, the National Screening Committee recommended that HPV 
primary testing be adopted in the United Kingdom12 and the cancer outcomes strategy for 
England13 recommended national rollout by 2020. Six English sites have been piloting HPV 
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primary screening since 2013 on approximately 13% of the screened population, with the 
intention of a future national rollout. Public Health England (PHE) and the National Health 
Service (NHS) who are responsible for the screening programme in England have until 
recently aimed to switch-over in April 2019,14 but are now working towards a December 
2019 deadline.  
Where national screening programmes are already extremely effective, switching to a more 
sensitive screening test may not be perceived as urgent. The cytology-based UK screening 
programme is highly effective in identifying and treating pre-invasive cervical lesions.15 
Consequently, cervical cancer is rare among screened women and it may be presumed that 
short delays in replacing cytology with HPV testing will have negligible consequences.  
Here, we estimated the excess number of screened women who will develop cervical cancer 
and the associated lost quality-adjusted life years (QALYs) under a scenario where the 
introduction of HPV screening is postponed by one year while cytology-based screening 
continues. A QALY is a generic measure of disease burden, including both the quality and 
the quantity of life lived. Institutions such as the National Institute for Health and Care 
Excellence (NICE) use this indicator of health benefit to compare various health interventions 
and typically only recommend treatments if their cost per QALY is less than £20,000-
£30,000. With this method, we estimated the monetary value of a timely HPV screening 
implementation using England as an example.  
There is risk associated with overly rapid implementation. We do not attempt to quantify 
them here. Rather we calculate the benefits of early adoption and argue that these should be 
taken into account during the planning phase. 
Estimating the cost of postponing the implementation of HPV testing 
We estimated the excess in cervical cancers among women in England in a scenario where 
HPV primary screening is rolled-out nationally a year later than planned (in this example, in 
December 2020 instead of December 2019) (Table 1). We tackle this in two steps. First, we 
estimate cancer incidence to 2030 assuming cytology-based screening (3- and 5-yearly 
depending on age) and vaccination against HPV 16 and 18 is offered to cohorts born from 
1990. We use data modelling for this.16 Separately, we estimate the proportion of cancers that 
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would have been prevented by HPV testing by using data from a population-based case 
control study.15 In both steps we assume that age-specific screening-coverage remains as in 
2014/15 (Table 2).17 
The first time the HPV test is offered to women as the primary screening test (i.e. the 
prevalence round), women will benefit if they are HPV positive but cytology negative – 
instead of receiving a 3/5-year interval they are re-called earlier and treated, if necessary. We 
use screening histories from the case control study15 to estimate (by age group and FIGO 
stage) the proportion of women with a negative cytology test prior to diagnosis. We exclude 
cancers diagnosed within 18 months of a negative test because, for these cancers, it is likely 
too late to prevent the cancer by treating preinvasive disease. However, we include cancers 
diagnosed up to and including 1.5 years after the next screen (because by screening now we 
might be able to prevent those screen-detected on the next screen), Table 1. Not all the 
cancers diagnosed following a negative test would have been preventable had the test been 
HPV rather than cytology. We have previously estimated18 that although 37.8% of cancers 
had a negative cytology in the appropriate window, only 23.9% (i.e. 63.2% of those with 
negative cytology) additional cancers would be prevented by primary HPV testing. To take 
this into account, we multiply the (age- and FIGO stage-specific) proportions of women with 
negative cytology by 0.632, Table 1. Full methodological details can be found in appendix 1. 
Age- and stage-specific 5-year case fatality rates were taken from published literature.19 Ten-
year cervical cancer relative survival20 is only slightly lower than the 5-year survival. Hence, 
for fatal cases we assumed that on average women survive 2.5 years and that survivors have 
the same remaining life expectancy as the general population.  
The assumptions underlying the women’s life expectancy, the estimation of lost QALYs and 
its monetary value resulting from failing to prevent cervical cancer were all based on 
published parameters (Table 3). The total number of QALYs that would be saved with the 
switch to HPV-based screening in 2019 instead of 2020 was discounted to present value in 
2019, to account for the society’s tendency to prefer immediate benefits rather than those 
accruing in the distant future. As recommended by NICE, we present results discounted with 
two interest rates, 1.5% and 3.5%.21 Finally, the discounted QALYs were multiplied by 
NICE’s lower threshold incremental cost-effectiveness ratio, £20,000.21  
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Impact of postponing the introduction of primary HPV testing 
At present, approximately 2500 cases of cervical cancer are diagnosed each year in 
England.22 We estimate that by 2030, 581 more could be prevented by  introducing primary 
HPV testing in December 2019 rather than December 2020. A comparison of this figure to 
other published estimates and a discussion on how a change in screening interval could 
impact the results is presented in appendix 2. Sixty percent of those 581 cancers would have 
been diagnosed under age 50 and three-quarters at FIGO stage 1 (Table 1). Together these 
581 women would lose 1595 QALYs using a 3.5% discount rate (2285 using 1.5%).  
The monetary value of these QALYs, i.e. a saving with a timely implementation of HPV-
based screening, is between £32 and £46 million, depending on discounting, over the 
women’s expected life spans. This means that for every month the implementation is 
postponed, 48 additional women will be diagnosed with cervical cancer at an estimated value 
of £2.7-3.8 million in terms of QALYs.  
We have deliberately used conservative assumptions in our analysis. We assumed that all 
women who survive the first 5 years after cancer diagnosis will have normal life spans, we 
have not taken into account the particularly severe QALY detriments during palliative care, 
the loss of quality of life among survivors was considered life-long and hence more affected 
by discounting, and we used the lower incremental cost-effectiveness threshold 
recommended by NICE.   
Although these estimates are specific to England, they are informative for other countries. In 
fact, the opportunity cost of postponing HPV-based screening may be even greater in 
countries with less rigorous quality assurance and lower sensitivity of cytology than 
England.23 We have not attempted to estimate the cost to the health service of implementing 
change more rapidly, but we do discus these and other considerations in appendix 3.   
The challenge of introducing new technologies into established 
programmes and implementation pitfalls 
Making a change as profound as switching to a different screening test in a successful 
screening programme is no small task. The first challenge is obtaining official backing to 
implement a new screening test (or another health care policy). Once the decision to 
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implement a new technology is made, there is a risk that it could need to be reverted, causing 
reputational damage and sunk costs. In the case of HPV screening, this scenario is unlikely.  
The second challenge is preparing for the roll-out, during which aspects such as changes in 
laboratory organisation, contracting, staffing, quality assurance and, not least, revised 
management guidelines, all need to be considered and this takes time. Reducing the time 
devoted to planning and preparing a roll-out to ensure earlier implementation could 
jeopardise the quality of the service, so realistic timescales and appropriate upfront 
investment are key to timely implementation of any new public health intervention. A 
multitude of factors can negatively affect the process. Evidence from organised screening 
programmes in Europe and elsewhere demonstrate that even after the new policy has been 
agreed a timely implementation thereafter is not guaranteed, and implementation delays 
experienced elsewhere can offer instructive examples.  
 Population based call/recall databases underpin the running of organised screening 
programmes. Australia recently commissioned a single National Cancer Screening Register 
with the objective of bringing together a number of existing databases. However, developing 
and implementing a screening registry solution, and the migrating of existing databases, 
turned out to be more complex than expected and this postponed the implementation date of 
HPV screening from May to December 2017. As a result, additional investment from the 
Government was needed to ensure continuation of cytology screening and staff retention.24  
Similarly, the existing screening databases in England are unable to cope with the changes 
afoot. In 2015 Capita, an FTSE 100 outsourcer, began a £1bn contract to supply 
administrative support to NHS England. This contract included a redevelopment of the 
primary care support services (PCS) database, which handles several primary care services 
including GP payments and screening call/recall. Unfortunately, the complexities of the 
call/recall part of the PCS database were poorly specified. Capita’s original commitment was 
to introduce a standardised national screening database by June 2017.25 There have been a 
number of complications and it is currently unclear when the database is expected to be ready 
for testing. Other countries could potentially avoid delays by considering computer systems 
that are purpose-built for screening.26 These could offer a platform that can more readily 
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overcome the complexities of screening data while still allowing a degree of individual 
tailoring. 
It is often unpredictable external factors that derail the implementation process even when it 
is reasonably well planned. The Netherlands was the first European country to announce its 
intention to implement HPV-based screening. The process of change was organised across 
several years and planned in detail.27 In 2015, however, this process was almost halted 
because of a media scandal due to incomplete disclosure of potential conflicts of interest of 
one of the country’s leading HPV researchers. Also, the country opted for centralised 
procurement of a single HPV assay and then faced lengthy legal battles with the unsuccessful 
competitors. Consequently, the implementation was delayed until early 2017.  
Finally, announcing a profound change in policy can have unexpected consequences. In 
England, for example, uncertainty around laboratory configuration once HPV primary 
screening is implemented has begun affecting the cytology screening programme. Since the 
laboratories began reorganising in 2012 to support the use of HPV testing for triage of low-
grade abnormal cytology and test of cure, the proportion of women who receive their 
screening test result within two weeks (one of the key performance indicators) has fallen 
from the target 98% in 2012/13 to 71.6% in 2016/17.22 This has been attributed to the 
increasing difficulty to maintain staff numbers because cyto-screening is no longer an 
attractive or secure profession. 
What are the wider implications? 
In future, the benefits as well as the risks of more rapid implementation of innovations of 
proven efficacy should be formally evaluated at the beginning of the process. With such 
planning countries could have allowed pilots of primary HPV testing for cervical screening to 
have been set up in 2007 with national rollout five years later, by 2012. In England, had 
rollout happened seven years earlier than it is now planned, by 2030 some 4,000 fewer 
women would experience cervical cancer, leading to a QALY gain with a value of at least 
£224 million. In the case of HPV primary testing, this loss is even more troublesome because 
screening can be done just as safely at longer intervals,28 which should be cost saving to the 
NHS. At present, screening programme and treatment costs amount to £157 million per 
year.29 It is expected that the cost of 6- and 10-yearly HPV-based screening would be about 
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half that of 3- and 5-yearly cytology based screening, leading to an additional direct saving of 
ca. £75million per year (or ~£500million over 7 years).  
While careful planning is essential, sometimes there is a heavy price to pay for being 
overcautious. 
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TABLES 
Table 1. Estimated number of excess cervical cancer cases in England by FIGO stage and age 
at diagnosis resulting from delaying replacing cytology with primary HPV screening for 12 
months, and 5-year case fatality rates.  
 
 
Age at 
diagnosis 
(years) 
Estimated 
yearly 
number of 
cancers 
diagnosed 
with 
continued 
cytology 
screening1 
Observed 
proportion 
of women 
with a 
negative 
cytology test 
prior to 
diagnosis2 
Proportion 
of cancers 
prevented 
by HPV 
primary 
screening3 
Total 
excess 
cancers 
Stage 
1A 
Stage 
1B 
Stage 
2 
Stage 
3+ 
        Excess number of cervical cancers* 
25-29 314.5 19.2 12.1 38.1 21.2 13.6 2.6 0.8 
30-34 398.9 40.0 25.3 100.7 58.2 35.4 4.9 2.2 
35-39 392.2 37.3 23.6 92.5 43.2 41.6 5.8 1.9 
40-44 289.2 35.9 22.7 65.6 28.7 28.3 6.5 2.1 
45-49 241.8 35.1 22.2 53.6 18.6 26.0 6.0 3.1 
50-54 229.3 28.2 17.8 40.9 8.7 18.9 8.1 5.2 
55-59 207.9 40.9 25.8 53.7 10.5 24.3 10.9 8.0 
60-64 168.9 37.7 23.8 40.3 8.8 14.2 9.9 7.4 
65-69 192.2 27.1 17.1 32.9 2.8 12.7 7.4 9.9 
70-74 168.9 38.0 24.0 40.6 1.6 10.4 13.8 14.8 
75-79 169.5 20.2 12.8 21.7 1.8 4.7 9.2 5.9 
Total 2773.3     580.5 204.0 230.1 85.1 61.3 
        5-year case-fatality rates (%)19 
25.5-34       -- 1.4 8.8 55.1 80 
35-49       -- 1.4 8.6 54.2 79.2 
50-64       -- 2.5 10.9 51.2 86 
65-69       -- 2.1 9.1 44.9 80.5 
70-74 
(79) 
      -- 1.5 14.8 68.8 95.1 
1For women aged 25 to 59 the observed cancers is an average of the estimated annual cervical cancers 
diagnosed between 2016-20 and 2021-25. For women aged 60-79 it is an average of the yearly number of 
cancers diagnosed from 2016 to 2030. 
2 Negative cytology test between 1.5-4.5 years prior to diagnosis at age 25-49; between 1.5-6.5 years at age 
50-59 and between 1.5-11.5yrs (at age 60 to 65) prior to diagnosis for those aged 60-79. 
3 We estimate the proportion prevented by HPV primary screening using the formula: Obs*0.632, where 
Obs= observed proportion with negative test 
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Table 2. Screening coverage in England in 2014/15 
by age group 
Age group 
Cervical cancer screening coverage 
in 2014/151 
Regularly 
screened  
Lapsed Never 
25-292 63.5% - 36.5% 
30-34 70.4% 14.8% 14.8% 
35-39 73.1% 17.4% 9.5% 
40-44 75.1% 17.6% 7.3% 
45-49 75.2% 17.9% 6.9% 
50-54 80.8% 12.1% 7.1% 
55-59 74.6% 17.1% 8.3% 
60-64 72.4% 17.9% 9.7% 
1 Observed in 2014/15 Cervical screening programme 
statistics,17 table 3 (regularly screened defined as test within 
3.5yrs aged 25-49 and within 5.5yrs aged 50-64).  
2 Since women are first invited for screening at age 25, women 
in this age group cannot be lapsed. 
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Table 3. Parameters used in the estimation of the monetary value of lost QALYs associated 
with a one-year delay in the implementation of HPV-based cervical screening. 
Parameter Value Source 
Remaining life 
expectancya 
25-29 years 56.36 years 
30-34 years 51.46 years 
35-39 years 46.59 years 
40-44 years 41.77 years 
45-49 years 37.02 years 
50-54 years 32.35 years 
55-59 years 27.81 years 
60-64 years 23.42 years 
65-69 years 19.20 years 
70-74 years 15.22 years 
 
Office for 
National 
Statistics30  
Age-specific QALYs 
for the general 
populationb 
25-34 years 0.868 
35-44 years 0.864 
45-54 years 0.824 
55-64 years 0.803 
65-74 years 0.766 
≥75 years 0.742 
 
Janssen and 
Szende31 
QALY detriments 
because of cervical 
cancer 
Diagnosis, treatment -0.285 for 0.116 years 
Recovery 
Linear change from -
0.285 to -0.0305 in 1.5 
years 
Rest of life -0.0305  
 
Jit et al.32, 33 
Threshold 
incremental cost-
effectiveness ratio 
£20,000 NICE21 
Notes. We used the following assumptions: (a) women were born on 1st July, (b) cervical 
cancers were diagnosed on 1st July when women reached the middle age of the respective age 
group, e.g. 27 for age group 25-29 years, (c) women with fatal cervical cancers died in on 
average 2.5 years after the diagnosis. These deaths represent the total mortality from cervical 
cancer.   
a This is the average life expectancy that patients would have had they not developed a fatal 
cervical cancer. In our analysis, the remaining life expectancy for an age group was taken for 
year of age in the middle of the age group, e.g. at age 27 for age group 25-29. 
b This is the average quality of life, on a scale from 0 to 1, that patients would experience 
throughout their life had they not developed cervical cancer. Women without cancer were 
assumed to have the same quality of life as the general population. These so-called population 
norms for English women show a decreasing average quality of life with increasing age, 
meaning that that as women age, there are progressively fewer QALYs that can be saved from 
preventing cervical cancer. Once a woman dies from the cancer, the QALYs that would have 
been experienced in absence of cancer are assumed to be lost. 
 
 
